In ARID1A-deficient tumors, such as bladder cancer, the loss of ARID1A leads to a transcriptional-translational conflict, resulting in an accumulation of pro-proliferative transcripts while inhibiting eEF2 function. Here, ARID1A is linked to urinary bladder carcinoma.